According to ImmunoGen
's latest financial reports the company's current revenue (TTM ) is $0.28 Billion USD. In 2022 the company made a revenue of $0.10 Billion USD an increase over the revenue in the year 2021 that were of $69.85 Million USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.28 B | 164.39% |
2022 | $0.10 B | 55.72% |
2021 | $69.85 M | -47.2% |
2020 | $0.13 B | 60.81% |
2019 | $82.27 M | 53.93% |
2018 | $53.44 M | -53.71% |
2017 | $0.11 B | |
2015 | $56.91 M | -23.21% |
2014 | $74.12 M | -2.61% |
2013 | $76.11 M | 489.68% |
2012 | $12.9 M | -40.98% |
2011 | $21.86 M | 42.7% |
2010 | $15.32 M | -18.2% |
2009 | $18.73 M | -45.75% |
2008 | $34.53 M | -12.68% |
2007 | $39.54 M | 5.27% |
2006 | $37.56 M | 17.28% |
2005 | $32.02 M | -8.37% |
2004 | $34.95 M | 194.75% |
2003 | $11.85 M | 53.32% |
2002 | $7.73 M | 44.88% |
2001 | $5.33 M | -29.78% |
2000 | $7.6 M | -23.2% |
1999 | $9.9 M | 890% |
1998 | $1 M | 150% |
1997 | $0.4 M | 0% |
1996 | $0.4 M |